Search
Descriptor English: Adalimumab
Descriptor Spanish: Adalimumab
Descriptor adalimumab
Entry term(s) Adalimumab-adbm
Adalimumab-atto
Amjevita
Cyltezo
Scope note: Un anticuerpo monoclonal humanizado que se une específicamente a TNF-ALFA y bloquea su interacción con RECEPTORES de TNF endógenas para modular la INFLAMACIÓN. Se utiliza en el tratamiento de la ARTRITIS REUMATOIDE ; ARTRITIS PSORIÁSICA ; ENFERMEDAD DE CROHN y la COLITIS ULCEROSA.
Descriptor Portuguese: Adalimumab
Descriptor French: Adalimumab
Entry term(s): Adalimumab-adbm
Adalimumab-atto
Amjevita
Antibody, D2E7
Cyltezo
D2E7 Antibody
Humira
Tree number(s): D12.776.124.486.485.114.224.060.250
D12.776.124.790.651.114.224.060.250
D12.776.377.715.548.114.224.200.250
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000068879
Scope note: A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Anti-Inflammatory Agents
Antirheumatic Agents
Registry Number: FYS6T7F842
Public MeSH Note: 2016; ADALIMUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2002-2015
History Note: 2016 (2002)
Related: Tumor Necrosis Factor-alpha MeSH
DeCS ID: 55973
Unique ID: D000068879
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2016/01/01
Date of Entry: 2015/07/01
Revision Date: 2017/12/14
Adalimumab - Preferred
Concept UI M0422769
Scope note A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
Preferred term Adalimumab
Humira - Narrower
Concept UI M0444260
Preferred term Humira
Adalimumab-adbm - Narrower
Concept UI M000638622
Preferred term Adalimumab-adbm
Amjevita - Narrower
Concept UI M000638102
Preferred term Amjevita
Adalimumab-atto - Narrower
Concept UI M000638621
Preferred term Adalimumab-atto
Cyltezo - Narrower
Concept UI M000638106
Preferred term Cyltezo
D2E7 Antibody - Narrower
Concept UI M000638385
Preferred term D2E7 Antibody
Entry term(s) Antibody, D2E7



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey